NDAORALTABLET
Approved
Feb 2012
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
KORLYM (mifepristone) by Corcept Therapeutics is progestational hormone receptor antagonists [moa]. Approved for cushing's syndrome. First approved in 2012.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KORLYM (mifepristone) is an oral progestin antagonist approved in 2012 for an indication requiring glucocorticoid receptor antagonism. As a progestational hormone receptor antagonist, it blocks progesterone signaling pathways and is currently in peak lifecycle stage with established market presence. The drug represents a unique mechanism in its therapeutic class with limited direct competition.
$0.2BPart D
12.3 years to LOEMechanism of Action
Progestational Hormone Receptor Antagonists
Pharmacologic Class:
Progestin Antagonist
Indications (1)
Clinical Trials (20)
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
Started Oct 2023
201 enrolled
Metastatic Breast Cancer
Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)
Started Mar 2023
1,113 enrolled
HypercortisolismDiabetes Mellitus, Type 2
Mifepristone Dynamic Testing for Diagnosis for Central Adrenal Insufficiency
Started May 2021
3 enrolled
Central Adrenal InsufficiencyMifepristone
Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome
Started Sep 2017
2 enrolled
HypercortisolismCushing Syndrome
Crossover Drug-Drug Interaction Study to Determine Effects of Cytochrome P450 3A on Exposure to Mifepristone and Its Metabolites
Started Aug 2017
48 enrolled
Healthy
Worked on KORLYM at Corcept Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.